TWST
VENTE TOTALE: 209 539 titres (~26 895 780,10 $ US)
- Insiders
- Leproust Emily M., BLAKE KATRYN, CHESS ROBERT
- Total bought
- —
- Total sold
- $26,895,780
- Last activity
- 2026-09-08
- Last synced
-
2026-09-11 10:16:43
Insider holdings as a share of total assets aren't available for this company.
Price (1 year)
Live chart from TradingView - pulls its own market data, independent of this site's database. Symbol resolution is best-effort (defaults to NASDAQ) since we don't store the exchange prefix.
Market snapshot
Signal
Bearish signal Scored 2026-09-10
Despite TWST's encouraging operational improvements and margin expansion, the catalytic picture is deeply negative: massive insider selling of $26.9M signals a lack of conviction from insiders, while a short report and…
The first sentence of the analysis written for TWST on 2026-09-10 - a real excerpt, not a sample. The rest of it, the 0-100 score and the rating it produced are part of Plus. See plans.
Financial ratios
| Metric | Trend | 2025-09-30 | 2024-09-30 | 2023-09-30 | 2022-09-30 | 2021-09-30 |
|---|---|---|---|---|---|---|
| Gross Profit Margin | 50.7% | 42.6% | 36.6% | 41.4% | 39.1% | |
| Ebit Margin | -20.4% | -66.5% | -83.0% | -112.1% | -116.1% | |
| Ebitda Margin | -13.8% | -56.5% | -71.1% | -104.0% | -108.7% | |
| Operating Profit Margin | -36.2% | -70.6% | -88.6% | -115.3% | -115.4% | |
| Pretax Profit Margin | -20.4% | -66.5% | -83.0% | -112.1% | -116.4% | |
| Continuous Operations Profit Margin | -20.6% | -66.7% | -83.5% | -107.0% | -114.9% | |
| Net Profit Margin | -20.6% | -66.7% | -83.5% | -107.0% | -114.9% | |
| Bottom Line Profit Margin | -20.6% | -66.7% | -83.5% | -107.0% | -114.9% | |
| Current Ratio | 3.643 | 4.884 | 5.786 | 6.579 | 8.667 | |
| Quick Ratio | 3.333 | 4.545 | 5.349 | 6.146 | 8.163 | |
| Solvency Ratio | -0.313 | -1.252 | -1.146 | -1.171 | -1.174 | |
| Cash Ratio | 2.003 | 3.187 | 3.907 | 4.177 | 7.388 | |
| Price To Earnings Ratio | -21.646 | -12.550 | -5.628 | -8.723 | -33.959 | |
| Price To Earnings Growth Ratio | 0.339 | 0.000 | 0.517 | -0.309 | 2.886 | |
| Forward Price To Earnings Growth Ratio | 0.339 | 0.000 | 0.517 | -0.309 | 2.886 | |
| Price To Earnings Diluted Ratio | -21.646 | -12.550 | -5.628 | -8.723 | -33.959 | |
| Price To Earnings Diluted Growth Ratio | 0.339 | 0.000 | 0.517 | -0.309 | 2.886 | |
| Price To Book Ratio | 3.558 | 5.545 | 1.849 | 2.406 | 8.886 | |
| Price To Sales Ratio | 4.469 | 8.375 | 4.702 | 9.328 | 39.003 | |
| Price To Free Cash Flow Ratio | -22.252 | -37.895 | -6.769 | -8.393 | -37.051 | |
| Price To Operating Cash Flow Ratio | -35.336 | -40.896 | -8.089 | -15.266 | -45.984 | |
| Debt To Assets Ratio | 0.214 | 0.138 | 0.121 | 0.099 | 0.090 | |
| Debt To Equity Ratio | 0.290 | 0.180 | 0.151 | 0.120 | 0.108 | |
| Debt To Capital Ratio | 0.225 | 0.152 | 0.131 | 0.107 | 0.098 | |
| Long Term Debt To Capital Ratio | 0.115 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Financial Leverage Ratio | 1.357 | 1.300 | 1.245 | 1.218 | 1.209 | |
| Working Capital Turnover Ratio | 1.456 | 0.999 | 0.572 | 0.412 | 0.338 | |
| Operating Cash Flow Ratio | -0.521 | -0.903 | -1.943 | -1.372 | -1.780 | |
| Operating Cash Flow Sales Ratio | -0.126 | -0.205 | -0.581 | -0.611 | -0.848 | |
| Free Cash Flow Operating Cash Flow Ratio | 1.588 | 1.079 | 1.195 | 1.819 | 1.241 | |
| Debt Service Coverage Ratio | -3.821 | -6,112.586 | -35,060.600 | -2,515.863 | -73.987 | |
| Interest Coverage Ratio | 0.000 | -7,614.862 | -43,431.800 | -2,934.700 | -416.147 | |
| Short Term Operating Cash Flow Coverage Ratio | -3.446 | 0.000 | 0.000 | 0.000 | -72.322 | |
| Operating Cash Flow Coverage Ratio | -0.347 | -0.754 | -1.515 | -1.311 | -1.784 | |
| Capital Expenditure Coverage Ratio | -1.701 | -12.627 | -5.129 | -1.221 | -4.148 | |
| Dividend Paid And Capex Coverage Ratio | -1.701 | -12.627 | -5.129 | -1.221 | -4.148 | |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 | 0.000 | 0.000 | |
| Enterprise Value Multiple | -31.427 | -14.034 | -5.513 | -7.630 | -33.066 |
Sparkline shows each ratio oldest → newest (left → right).
How the latest year compares
For each ratio: its most recent value, the change versus one year earlier, and versus its 5-year average. ▲ higher ▼ lower
| Metric | Current | vs 1Y ago | vs 5Y avg |
|---|---|---|---|
| Gross Profit Margin | 50.7% | ▲8.1% | ▲8.6% |
| Ebit Margin | -20.4% | ▲46.1% | ▲59.2% |
| Ebitda Margin | -13.8% | ▲42.6% | ▲57.0% |
| Operating Profit Margin | -36.2% | ▲34.4% | ▲49.0% |
| Pretax Profit Margin | -20.4% | ▲46.1% | ▲59.3% |
| Continuous Operations Profit Margin | -20.6% | ▲46.1% | ▲57.9% |
| Net Profit Margin | -20.6% | ▲46.1% | ▲57.9% |
| Bottom Line Profit Margin | -20.6% | ▲46.1% | ▲57.9% |
| Current Ratio | 3.643 | ▼-1.241 | ▼-2.269 |
| Quick Ratio | 3.333 | ▼-1.212 | ▼-2.174 |
| Solvency Ratio | -0.313 | ▲0.939 | ▲0.698 |
| Cash Ratio | 2.003 | ▼-1.185 | ▼-2.130 |
| Price To Earnings Ratio | -21.646 | ▼-9.096 | ▼-5.145 |
| Price To Earnings Growth Ratio | 0.339 | ▲0.339 | ▼-0.348 |
| Forward Price To Earnings Growth Ratio | 0.339 | ▲0.339 | ▼-0.348 |
| Price To Earnings Diluted Ratio | -21.646 | ▼-9.096 | ▼-5.145 |
| Price To Earnings Diluted Growth Ratio | 0.339 | ▲0.339 | ▼-0.348 |
| Price To Book Ratio | 3.558 | ▼-1.987 | ▼-0.890 |
| Price To Sales Ratio | 4.469 | ▼-3.906 | ▼-8.706 |
| Price To Free Cash Flow Ratio | -22.252 | ▲15.642 | ▲0.220 |
| Price To Operating Cash Flow Ratio | -35.336 | ▲5.559 | ▼-6.222 |
| Debt To Assets Ratio | 0.214 | ▲0.075 | ▲0.082 |
| Debt To Equity Ratio | 0.290 | ▲0.111 | ▲0.120 |
| Debt To Capital Ratio | 0.225 | ▲0.073 | ▲0.082 |
| Long Term Debt To Capital Ratio | 0.116 | ▲0.116 | ▲0.092 |
| Financial Leverage Ratio | 1.357 | ▲0.058 | ▲0.091 |
| Working Capital Turnover Ratio | 1.456 | ▲0.457 | ▲0.701 |
| Operating Cash Flow Ratio | -0.521 | ▲0.382 | ▲0.783 |
| Operating Cash Flow Sales Ratio | -0.127 | ▲0.078 | ▲0.348 |
| Free Cash Flow Operating Cash Flow Ratio | 1.588 | ▲0.509 | ▲0.203 |
| Debt Service Coverage Ratio | -3.821 | ▲6108.765 | ▲8749.550 |
| Interest Coverage Ratio | 0.000 | ▲7614.862 | ▲10879.502 |
| Short Term Operating Cash Flow Coverage Ratio | -3.446 | ▼-3.446 | ▲11.708 |
| Operating Cash Flow Coverage Ratio | -0.347 | ▲0.407 | ▲0.795 |
| Capital Expenditure Coverage Ratio | -1.701 | ▲10.926 | ▲3.264 |
| Dividend Paid And Capex Coverage Ratio | -1.701 | ▲10.926 | ▲3.264 |
| Dividend Payout Ratio | 0.000 | 0.000 | 0.000 |
| Enterprise Value Multiple | -31.427 | ▼-17.393 | ▼-13.093 |
Key metrics
| Metric | Trend | 2025 | 2024 | 2023 | 2022 | 2021 |
|---|---|---|---|---|---|---|
| Market cap | $1.68B | $2.62B | $1.15B | $1.90B | $5.16B | |
| Enterprise value | $1.64B | $2.48B | $960.1M | $1.62B | $4.76B | |
| EV / Sales | 4.35x | 7.92x | 3.92x | 7.93x | 35.96x | |
| EV / Op. cash flow | -34.38x | -38.69x | -6.74x | -12.98x | -42.39x | |
| EV / Free cash flow | -21.65x | -35.85x | -5.64x | -7.14x | -34.16x | |
| EV / EBITDA | -31.43x | -14.03x | -5.51x | -7.63x | -33.07x | |
| Net debt / EBITDA | 0.88x | 0.80x | 1.10x | 1.34x | 2.80x | |
| Current ratio | 3.64x | 4.88x | 5.79x | 6.58x | 8.67x | |
| Income quality | 0.61x | 0.31x | 0.70x | 0.57x | 0.74x | |
| Graham net-net | $2 | $3 | $4 | $7 | $8 | |
| Tax burden | 100.9% | 100.3% | 100.6% | 95.4% | 98.7% | |
| Interest burden | 100.0% | 100.0% | 100.0% | 100.0% | 100.2% | |
| Working capital | $241.6M | $275.8M | $350.9M | $505.8M | $483.4M | |
| Invested capital | $488.8M | $537.4M | $694.6M | $865.8M | $629.8M | |
| Return on assets | -12.1% | -34.0% | -26.4% | -22.7% | -21.7% | |
| Operating ROA | -21.7% | -31.8% | -25.0% | -28.2% | -27.7% | |
| Return on tangible assets | -14.2% | -40.6% | -32.2% | -26.7% | -23.0% | |
| Return on equity | -16.4% | -44.2% | -32.8% | -27.6% | -26.2% | |
| Return on invested capital | -24.1% | -39.6% | -30.2% | -25.3% | -23.2% | |
| Return on capital employed | -24.8% | -40.6% | -30.9% | -27.0% | -23.9% | |
| Earnings yield | -4.6% | -8.0% | -17.8% | -11.5% | -2.9% | |
| Free cash flow yield | -4.5% | -2.6% | -14.8% | -11.9% | -2.7% | |
| Capex / Op. cash flow | -58.8% | -7.9% | -19.5% | -81.9% | -24.1% | |
| Capex / Depreciation | 112.7% | 16.1% | 94.8% | 616.8% | 277.5% | |
| Capex / Sales | 7.4% | 1.6% | 11.3% | 50.0% | 20.4% | |
| SG&A / Sales | 65.6% | 69.8% | 77.4% | 104.6% | 102.7% | |
| R&D / Sales | 21.3% | 29.0% | 43.6% | 59.1% | 52.2% | |
| Stock comp / Sales | 17.1% | 16.3% | 12.4% | 39.1% | 28.0% | |
| Intangibles / Total assets | 14.9% | 16.3% | 18.1% | 15.1% | 5.8% | |
| Days sales outstanding | 56d | 41d | 66d | 72d | 79d | |
| Days payables outstanding | 22d | 3d | 33d | 61d | 67d | |
| Operating cycle | 111d | 90d | 141d | 192d | 223d | |
| Cash conversion cycle | 89d | 86d | 108d | 131d | 155d |
Change by theme
Grouped by what each metric measures. Each figure is the change over the period shown — ▲ up ▼ down versus then.
Change over 1 year
Valuation
Market cap ▼-35.8%EV / Sales ▼-45.1%EV / EBITDA ▼-123.9%EV / Op. cash flow ▲+4.315Earnings yield ▲+0.033
Profitability
Return on equity ▲+0.277Return on assets ▲+0.219Return on invested capital ▲+0.154Return on capital employed ▲+0.159Operating ROA ▲+0.101Income quality ▲+0.306Tax burden ▲+0.007
Efficiency
Days sales outstanding ▲+14.853Days payables outstanding ▲+18.509Operating cycle ▲+21.607Cash conversion cycle ▲+3.098Capex / Sales ▲+0.058R&D / Sales ▼-0.077
Balance-sheet strength
Current ratio ▼-1.241Net debt / EBITDA ▲+0.078Working capital ▼-34210000.000Invested capital ▼-48568000.000Intangibles / Total assets ▼-0.014
Change over 5 years
Valuation
Market cap ▼-67.4%EV / Sales ▼-87.9%EV / EBITDA ▲+5.0%EV / Op. cash flow ▲+8.018Earnings yield ▼-0.017
Profitability
Return on equity ▲+0.098Return on assets ▲+0.096Return on invested capital ▼-0.009Return on capital employed ▼-0.009Operating ROA ▲+0.060Income quality ▼-0.125Tax burden ▲+0.022
Efficiency
Days sales outstanding ▼-23.186Days payables outstanding ▼-45.638Operating cycle ▼-111.476Cash conversion cycle ▼-65.839Capex / Sales ▼-0.130R&D / Sales ▼-0.309
Balance-sheet strength
Current ratio ▼-5.025Net debt / EBITDA ▼-1.922Working capital ▼-241883000.000Invested capital ▼-141001000.000Intangibles / Total assets ▲+0.091
Employee count
Peer market caps
Congressional trades
Recent trades
| Date | Representative | Type | Amount |
|---|---|---|---|
| 2020-03-01 | Dwight Evans | Purchase | $1,001 - $15,000 |
Recent news
- 2026-09-09 AI & Robotics in 2026: 16 Recent Developments for Investors If AI and robotics suddenly feel like they are moving faster, August gave investors plenty of evidence that the pace really is accelerating. We saw longer-running agents, faster and cheaper inference, AI systems reaching into laboratories and physical equipment, robots learning from fewer demonstrations, and new capital and infrastructure forming around commercial deployment.
- 2026-09-09 Twist Bioscience to Present at Baird 2026 Global Healthcare Conference SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--Twist Bioscience Corporation (NASDAQ: TWST), a mid-cap growth and value biotech company, today announced that Emily M. Leproust, Ph.D., CEO and co-founder of Twist Bioscience, and Adam Laponis, CFO of Twist Bioscience, will participate in a fireside chat at the Baird 2026 Global Healthcare Conference on Tuesday, September 15, 2026 at 1:25 pm Eastern Time in New York City. The fireside chat will be webcast live and can be accessed by visiting the “In.
- 2026-08-25 Brandywine Managers LLC Invests $2.16 Million in Twist Bioscience Corporation $TWST Brandywine Managers LLC acquired a new position in shares of Twist Bioscience Corporation (NASDAQ: TWST) during the second quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund acquired 20,970 shares of the company''s stock, valued at approximately $2,157,000. Twist Bioscience comprises
- 2026-08-24 90,053 Shares in Twist Bioscience Corporation $TWST Acquired by Deutsche Bank AG Deutsche Bank AG acquired a new stake in Twist Bioscience Corporation (NASDAQ: TWST) in the undefined quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor acquired 90,053 shares of the company''s stock, valued at approximately $9,265,000. Deutsche Bank AG owned about 0.14% of Twist
- 2026-08-20 Twist Biosciences: AI-Driven Rally Or Short Squeeze? I''m Neutral (For Now) Twist Bioscience Corporation is rated Hold, as its $9.5bn valuation appears disconnected from current fundamentals, and profitability remains elusive. TWST''s recent 200% stock surge is driven by AI-related news, short squeeze dynamics, and strong DSPS revenue growth, not by blowout earnings. Full-year 2026 guidance was raised to $456–$457m revenue with adjusted EBITDA breakeven targeted, but losses and elevated SG&A persist.
- 2026-08-19 Twist Bioscience Stock Resilient Despite Scorpion Capital Short Report Twist Bioscience Corp (NASDAQ:TWST) shares surged Wednesday after Anthropic named the company an independent evaluator in a new AI-driven protein design campaign.
- 2026-08-11 The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It’s Not Tech) Anthropic is preparing what could be the largest IPO of 2026, and it''s telling investors the pitch goes well beyond chatbots. According to the Wall Street Journal, "Anthropic is targeting a public debut in September or early October, people familiar with its plans said." In those same meetings, the company told some investors that it... The Biggest IPO of the Year Is Targeted in the Next 60 Days. Why One Unexpected Industry Could Rally Before Then (Hint: It''s Not Tech)
- 2026-08-07 Is Twist Bioscience Corp (TWST) Overvalued After 6.0% Rally? GF Value Says Overvalued On August 07, 2026, Twist Bioscience Corp (TWST) shares rose by 6.0%, bringing the current price to $115.67. The stock has experienced significant fluctuations,
- 2026-08-06 Twist Bioscience (NASDAQ:TWST) Shares Up 10.3% After Analyst Upgrade Twist Bioscience Corporation (NASDAQ: TWST - Get Free Report)''s share price shot up 10.3% during mid-day trading on Wednesday after Piper Sandler raised their price target on the stock from $85.00 to $115.00. Piper Sandler currently has an overweight rating on the stock. Twist Bioscience traded as high as $111.88 and last traded at $109.72. 593,619
- 2026-08-05 Twist Biosciences: Accelerating Growth, Diminishing Margin Of Safety Twist Bioscience''s stock has surged in 2026 on the back of improved growth and growing optimism about the AI-enabled drug discovery opportunity. Growth will be driven by triple-digit AI-enabled drug discovery order growth, and oncology diagnostic assay commercialization. Operating leverage, manufacturing improvements, and the introduction of higher value-add products will also see Twist''s margins continue to improve.